Sera Prognostics (SERA) to Release Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) will likely be posting its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect Sera Prognostics to post earnings of ($0.23) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Sera Prognostics Trading Up 1.0 %

Shares of SERA stock opened at $4.07 on Monday. The stock has a 50 day moving average of $5.29 and a two-hundred day moving average of $6.66. Sera Prognostics has a 12 month low of $3.84 and a 12 month high of $12.36. The company has a market capitalization of $137.45 million, a P/E ratio of -4.11 and a beta of 0.89.

Insiders Place Their Bets

In related news, General Counsel Benjamin Jackson sold 7,912 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $6.38, for a total transaction of $50,478.56. Following the completion of the transaction, the general counsel now owns 120,561 shares in the company, valued at $769,179.18. This trade represents a 6.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joshua Phillips sold 12,710 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $7.40, for a total value of $94,054.00. Following the transaction, the director now owns 5 shares of the company’s stock, valued at $37. This trade represents a 99.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,877 shares of company stock worth $480,677. 15.80% of the stock is currently owned by company insiders.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.